HLS Therapeutics (TSX:HLS) Interest Income : C$0.44 Mil (TTM As of Dec. 2024)

View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. HLS Therapeutics's interest income for the three months ended in Dec. 2024 was C$0.05 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.44 Mil.

HLS Therapeutics Interest Income Historical Data

The historical data trend for HLS Therapeutics's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Interest Income Chart

HLS Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Income

Get a 7-Day Free Trial

0.41

0.06

0.08

0.47

0.45

HLS Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Income	Get a 7-Day Free Trial															0.29	0.19	0.13	0.07	0.05

HLS Therapeutics Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.44 Mil.

HLS Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

HLTRF:USA

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.

Executives

Norma Beauchamp	Director
Jr. John Lee Welborn	Director
Craig Millian	Director, Senior Officer
Brian Thomas Walsh	Senior Officer
Polar Asset Management Partners Inc.	10% Security Holder
John Gordon Hanna	Director, Senior Officer
Athyrium Opportunities Ii Co-invest 1 Lp	10% Security Holder
Tim Hendrickson	Senior Officer
William M. Wells	Director, Senior Officer
Gilbert Godin	Director, Senior Officer
Gregory David Gubitz	Director
Orbimed Advisors Llc	10% Security Holder
Jason Gross	Senior Officer
Ryan Christopher Lennox	Senior Officer

HLS Therapeutics Headlines

No Headlines